<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2311200283
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Trientine dihydrochloride
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TRIENTINE DIHYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        8450.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Apothecon Pharmaceuticals PVT Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Apothecon Pharmaceuticals PVT Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 461]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            QOMEL MEDICAL DRUG STORE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Navinta LLC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A16AX12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Your medicine is called Trientine dihydrochloride 250 mg hard capsules. In this leaflet, it will be called as Trientine capsule.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Trientine dihydrochloride capsule is a medicine used for the treatment of Wilson&rsquo;s disease in adults, adolescents and children aged 5 years or older. It is for use by patients who cannot take another medicine, D-Penicillamine, because of side effects.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Trientine dihydrochloride contains the active substance trientine, a copper-chelating agent that is used to remove excess of copper from the body. Trientine dihydrochloride attaches to the copper, which is then passed from the body.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Clinical experience for this medicine is limited and therefore, alternate dosing regimens have not been well-characterized. This medicine can be used when continued treatment with penicillamine is no longer possible, but we cannot consider that Trientine dihydrochloride and penicillamine are interchangeable.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Trientine capsule:</strong></p><p dir="ltr">If you are allergic to trientine or any of the other ingredients of this medicine (listed in section 6).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Signs of an allergic reaction include rash, itching, swelling of the face, fainting and breathing problems.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor will need to regularly check for symptoms of the disease and copper levels in your blood and urine. Regular monitoring is especially important at the start of your treatment or when your dose is changed, in growing children and pregnant women to ensure that copper levels are maintained at a suitable level. The doctor may need to increase or decrease your dose of Trientine capsules.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Nervous system problems can occur (for example, shaking, lack of coordination, slurred speech, muscle stiffness and worsening of muscle spasms), especially in patients just starting treatment with Trientine capsule. If you notice these whilst taking Trientine capsules, you must tell your doctor immediately.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Lupus-like reactions (symptoms may include persistent rash, fever, joint pain, and tiredness) have been reported in some patients switched to trientine medicine after penicillamine medicine. However it was not possible to determine if the reaction was due to trientine or to previous penicillamine treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Other medicines and Trientine capsule</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are taking iron tablets or medicines that neutralise the acid in your stomach, leave at least 2 hours before or after you have taken Trientine capsules because they may reduce Trientine capsule&rsquo;s effect.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Trientine capsule with food and drink</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Take this medicine with water only. Do not take it with other drinks or food because they may reduce the medicine&rsquo;s effect. Avoid eating or drinking for 1 hour before, or 2 hours after taking Trientine capsules.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. It is very important to continue treatment to maintain normal copper levels during pregnancy. You and your doctor should fully discuss the potential benefits of treatment whilst considering any possible risks that there may be.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor will advise you which treatment and which dose is best in your situation. If you become pregnant whilst taking Trientine capsules, talk to your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are pregnant and taking Trientine capsules, you will be monitored throughout your pregnancy for any effects on the baby or changes in your copper levels.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;It is not known whether trientine is excreted in human milk, hence caution should be taken while prescribing to breast-feeding patient. It is important to tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding or to stop taking Trientine capsules, considering the benefit of breast-feeding to the baby and the benefit of Trientine capsules to the mother. Your doctor will decide which treatment and which dose is best in your situation.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Trientine is not likely to have an effect on your ability to drive or use machines.</p><p dir="ltr">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Adults (including the elderly)</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The usual dose is between 750 &ndash; 1250 mg per day given in 2 to 4 divided doses, to be taken by mouth.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Use in children and adolescents (5 to 17 years)</u></p><p dir="ltr">In children and adolescents, the dose depends on age and body weight and will be adjusted by your doctor. At the start of treatment the dose varies between 500 &ndash; 750 mg per day given in 2 to 4 divided doses.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor will decide the correct dose for you.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The total daily dose can be divided into 2 to 4 smaller doses, as indicated by your doctor. Swallow the capsules whole with a drink of water on an empty stomach, at least 1 hour before or 2 hours after food.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not open or chew the capsule.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients who have difficulties swallowing should contact their doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you take more Trientine capsule than you should</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">If you take more medicine than you should, you may get nausea, vomiting and dizziness. You must contact your doctor or another health care provider immediately.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you forget to take Trientine capsule</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">If you forget to take a dose take your next dose at its usual scheduled time. Do not take a double dose to make up for a forgotten dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you stop taking Trientine capsule</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">This medicine is for long-term use because Wilson&rsquo;s disease is a life-long condition. Do not stop or change your treatment without speaking with your doctor even if you feel better.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor or pharmacist</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them. Occasionally (<em>frequency unknown; cannot be estimated from available data</em>), treatment with this medicine can cause inflammation of the small intestine or colon. If you have any of the following side effects contact your doctor <strong>immediately</strong>:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe stomach pains</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Persistent diarrhoea</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nervous system problems (for example shaking, lack of coordination, slurred speech, muscle stiffness, worsening of muscle spasms).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Other side effects may include:</p><p dir="ltr"><em>Common (may affect up to 1 in 10 people)</em></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (especially when starting treatment)</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Uncommon (may affect up to 1 in 100 people)</em></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rashes</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (you may feel unusually tired)</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use after the expiry date which is stated on the bottle label and outer carton. The expiry date refers to the last day of the month.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Keep the container tightly closed. Store in the original container in order to protect from moisture.</p><p dir="ltr">Store in a refrigerator (2&ordm;C-8&ordm;C). Do not freeze.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.&nbsp; These measures will help to protect the environment.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is trientine. Each capsule contains 250 mg trientine dihydrochloride.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The other ingredients are</p><p dir="ltr"><u>Capsule content: </u></p><p dir="ltr">Stearic acid</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Capsule shell: </u></p><p dir="ltr">Gelatin</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">FD&amp;C Yellow 6 (E110)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cylindrical size “1” hard gelatin capsule with opaque orange colour cap printed with “NAV” in black ink and opaque white colour body printed with “101” in black ink.

White HDPE bottle with polypropylene cap and induction heat seal liner with a strips of silica gel as desiccant. 

Pack size: one bottle of 100 hard capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Marketing Authorisation Holder</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Navinta LLC</p><p dir="ltr">1499 Lower Ferry Road,</p><p dir="ltr">Ewing, NJ-08618-1414, USA</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Manufacturer</strong></p><p dir="ltr">Apothecon Pharmaceuticals Pvt. Limited</p><p dir="ltr">Plot No. 1134 to 1137, 1138-A&amp;B, 1143-B, 1144-A&amp;B,</p><p dir="ltr">Padra Jambusar Highway, Tal. Padra,</p><p dir="ltr">P.O. Dabhasa, District Vadodara,</p><p dir="ltr">State Gujarat &ndash; 391 440, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم دوائك هو ترينتين ديهايدروكلوريد 250 ملغ في كبسولات صلبة.&nbsp; وسنشير إليه في هذه النشرة باسم كبسولات ترينتين.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">كبسولات ترينتين ديهايدروكلوريد هو دواء يُستخدم لعلاج مرض ويلسون لدى البالغين والمراهقين والأطفال بعمر 5 سنوات أو أكبر. وهو مخصص للمرضى الذين لا يستطيعون تناول دواء آخر، أي دي-بنيسيلامين، بسبب آثاره الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي ترينتين ديهايدروكلوريد على المادة الفعالة ترينتين، وهي عامل مخلب للنحاس يستخدم لإزالة فائض النحاس من الجسم، حيث يرتبط ترينتين ديهايدروكلوريد بالنحاس ويخرجه من الجسم.</p><p dir="RTL">&nbsp;</p><p>الخبرة السريرية بهذا الدواء محدودة؛ ولذلك لم تُحدَّد أنظمة الجرعات البديلة جيدًا. يمكن استخدام هذا الدواء عندما لا يمكن الاستمرار في العلاج بالبنيسيلّامين؛ إلا أننا لا نستطيع اعتبار كلٍ من ترينتين ديهايدروكلوريد والبنيسيلّامين بديلًا للآخر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تناول كبسولات ترينتين:</strong></p><p dir="RTL">إذا كانت لديك حساسية تجاه ترينتين أو أي مكون من مكوناته الأخرى (المذكورة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل علامات رد الفعل التحسسي ظهور طفح جلدي والحكة وتورم الوجه والإغماء وصعوبة التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على طبيبك فحصك بانتظام لمراقبة أعراض المرض ومستويات النحاس في دمك وبولك. وتتسم المراقبة المنتظمة بأهمية خاصة في بداية العلاج أو عند تغيير الجرعة في حالات الأطفال والنساء الحوامل للتأكد من الحفاظ على النحاس في مستوى مناسب. وقد يحتاج الطبيب إلى زيادة أو خفض جرعتك من كبسولات ترينتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تحدث مشاكل في الجهاز العصبي (مثل الرجفة وضعف التنسيق الحركي والكلام غير المفهوم وتصلب العضلات وتفاقم التشنجات العضلية)، خاصة عند المرضى الذين يبدأون العلاج بكبسولات ترينتين لأول مرة. إذا لاحظت أياً من هذه الأعراض أثناء تناول كبسولات ترينتين فيجب عليك إبلاغ طبيبك فوراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن ردود فعل شبيهة بالذئبة (قد تشمل الأعراض طفحاً جلدياً مستمراً وحمى وآلاماً في المفاصل وإرهاقاً) لدى بعض المرضى الذين تحولوا إلى دواء ترينتين بعد تناول دواء البنيسيلامين. ولكن لم يمكن تحديد ما إذا كان رد الفعل ناتجاً عن ترينتين أو العلاج السابق بالبنيسيلامين.</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى وكبسولات ترينتين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول أقراص الحديد أو مضادات الحموضة التي تعمل على تحييد حمض المعدة، فاترك فاصلاً لا يقل عن ساعتين قبل أو بعد تناولك كبسولات ترينتين لأن تلك الأدوية قد تقلل من مفعول كبسولات ترينتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبسولات ترينتين مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول هذا الدواء مع الماء فقط، ولا تتناوله مع مشروبات أو أطعمة أخرى لأنها قد تقلل من مفعول الدواء. تجنب تناول الطعام أو الشراب لمدة ساعة واحدة قبل تناول كبسولات ترينتين ولمدة ساعتين بعد تناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً أو مرضعاً أو تظنين أنك ربما تكونين حاملاً أو تخططين لإنجاب طفل، فاستشيري طبيبك أو الصيدلي قبل تناول هذا الدواء. من المهم جداً مواصلة العلاج للحفاظ على النحاس في المستوى الطبيعي أثناء الحمل. ويجب أن تناقشي مع طبيبك الفوائد المحتملة للعلاج بشكل كامل مع مراعاة أي مخاطر محتملة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سينصحك طبيبك بالعلاج والجرعة المناسبين لوضعك. إذا أصبحت حاملاً أثناء تناول كبسولات ترينتين، فأخبري طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً وتناولتِ كبسولات ترينتين، فسيراقب الطبيب وضعك طوال فترة الحمل للكشف عن أي آثار على الطفل أو أي تغير في مستويات النحاس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس معروفًا ما إذا كان ترينتين يُفرَز في حليب الأم أم لا؛ ولذلك ينبغي توخِّي الحذر عند وصفه لمريضة مُرضِعة. من المهم أن تخبري طبيبك إذا كنت ترضعين طفلك أو تخططين لذلك، حيث سيساعدك الطبيب على تقرير ما إذا كان يجب التوقف عن الإرضاع الطبيعي أو التوقف عن تناول كبسولات ترينتين من خلال المفاضلة بين فائدة الرضاعة الطبيعية للطفل وفائدة كبسولات ترينتين للأم. وسيقرر طبيبك العلاج والجرعة المناسبين لوضعك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">من المستبعد أن يكون لترينتين تأثير على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعمل هذا الدواء دوماً حسب إرشادات طبيبك أو الصيدلي. وإذا كان لديك أي شك فاستشر طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>للبالغين (بما في ذلك كبار السن)</u></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">تتراوح الجرعة الإجمالية المعتادة بين 750 - 1250 ملغ يومياً، تُقسم إلى ما بين جرعتين إلى أربع جرعات جزئية، وتؤخذ عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>للأطفال والمراهقين (من 5 سنوات إلى 17 سنة)</u></p><p dir="RTL">تعتمد الجرعة في حالات الأطفال والمراهقين على العمر والوزن ويحددها الطبيب. في بداية العلاج، تتراوح الجرعة الإجمالية المعتادة بين 500 - 750 ملغ يومياً، تُقسم إلى ما بين جرعتين إلى أربع جرعات جزئية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>طريقة إعطاء الدواء</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك الجرعة المناسبة لك.</p><p>&nbsp;</p><p dir="RTL">يمكن تقسيم الجرعة اليومية الإجمالية إلى ما بين جرعتين إلى أربع جرعات جزئية، وفقاً لتعليمات الطبيب. ابتلع الكبسولات كاملة مع شرب الماء على معدة فارغة، وذلك قبل ساعة على الأقل من تناول الطعام أو بعد تناوله بساعتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تُفتَح الكبسولة أو تُمضَغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على المرضى الذين يعانون من صعوبات في البلع الاتصال بالطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تجاوز الجرعة المحددة من كبسولات ترينتين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تجاوزت الجرعة المحددة من الدواء، فقد تشعر بالغثيان والقيء والدوار. ويجب عليك الاتصال بطبيبك أو أي مزود رعاية صحية آخر على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول كبسولات ترينتين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت تناول جرعة في موعدها، فتناول الجرعة التالية في الوقت المحدد لها كالمعتاد، ولا تتناول جرعة مزدوجة للتعويض عن الجرعة التي نسيتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول كبسولات ترينتين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تناول هذا الدواء على المدى الطويل لأن مرض ويلسون هو مرض يستمر مدى الحياة. لا تتوقف عن تناول العلاج ولا تغيره دون التحدث مع طبيبك&nbsp; حتى وإن شعرت بتحسّن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أسئلة إضافية حول استعمال هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو حال جميع الأدوية، قد يسبب هذا الدواء بعض الآثار الجانبية، ولكنها لا تصيب الجميع. في بعض الحالات (لا تُعرف نسبتها ولا يمكن تقديرها بناء على البيانات المتاحة)، يمكن أن يسبب العلاج بهذا الدواء التهاباً في الأمعاء الدقيقة أو القولون. اتصل بطبيبك <strong>فوراً </strong>إذا شعرت بأي من الأعراض الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام شديدة في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال مستمر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الجهاز العصبي (مثل الرجفة وضعف التنسيق الحركي والكلام غير المفهوم وتصلب العضلات وتفاقم التشنجات العضلية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد تشمل الآثار الجانبية الأخرى ما يلي:</p><p dir="RTL">آثار جانبية شائعة (قد تصيب شخصاً واحداً من بين كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (خاصة عند بدء العلاج)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">آثار جانبية غير شائعة (قد تصيب شخصاً واحداً من بين كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (قد تشعر بالتعب بشكل غير عادي)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيداً عن مرأى الأطفال ومتناولهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المُبين على القارورة وعلى العلبة الكرتونية الخارجية. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">تأكد من إغلاق العبوة بإحكام. يجب حفظ الدواء في عبوته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">يُحفظ في البراد (في درجة حرارة بين 2 - 8 مئوية). لا تدع الدواء يتجمد.</p><p dir="RTL">يجب حفظ الدواء في عبوته الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم التخلص من الأدوية من خلال مياه الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي حول كيفية التخلص من الأدوية التي لم تعد تستعملها.&nbsp; فهذه الإجراءات ستساعد في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا تحتوي كبسولات ترينتين</strong></p><p dir="RTL">المادة الفعالة هي ترينتين. تحتوي كل كبسولة على 250 ملغ من ترينتين ديهايدروكلوريد</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل المكونات الأخرى ما يلي:</p><p dir="RTL"><u>محتوى الكبسولة:</u></p><p dir="RTL">حمض الميرستيك</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غلاف الكبسولة:</u></p><p dir="RTL">الجيلاتين</p><p dir="RTL">ثنائي أوكسيد التيتانيوم (E171)</p><p dir="RTL">مادة ملونة (D&amp;C Yellow 6) (E110)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قارورة بيضاء مصنوعة من مادة البولي إثيلين عالي الكثافة ولها غطاء مصنوع من مادة البولي بروبيلين وغطاء ورقي مثبت حرارياً مع قطع من هلام السيليكا لامتصاص الرطوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كبسولة جيلاتين صلبة دائرية الشكل قياس (1) تتكون من غطاء ذو لون برتقالي غامق طُبعت عليه الحروف &quot;NAV&quot; باللون الأسود وجسم أبيض طُبعت عليه الأرقام &quot;101&quot; باللون الأسود.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة: قارورة واحدة تحتوي على 100 كبسولة صلبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب تصريح التسويق</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">نافينتا ال ال سي</p><p dir="RTL">1499 لاور فيري رود،</p><p dir="RTL">إيوينج، نيوجيرسي 1414-08618، الولايات المتحدة الأمريكية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">أبوثيكون فارماسيوتكالز برايفت ليمتد</p><p dir="RTL">قطع الأرض رقم 1134 إلى 1137، 1138-(أ) و(ب)، 1143-(ب)، 1144-(أ) و(ب)،</p><p dir="RTL">طريق بادرا جامبوسار، تال، بادرا،</p><p dir="RTL">بي أو دابهاسا، مقاطعة فادودارا،</p><p dir="RTL">ولاية غوجارات &ndash; 440 391، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة آخر مرة في {سبتمبر / 2020}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trientine dihydrochloride 250 mg hard capsules USP
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Each hard capsule contains 250 mg trientine dihydrochloride.
For the full list of excipients see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.

Cylindrical size “1” hard gelatin capsule with opaque orange colour cap printed with “NAV” in black ink and opaque white colour body printed with “101” in black ink.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Trientine dihydrochloride is indicated for the treatment of Wilson&rsquo;s disease in patients intolerant to D-Penicillamine therapy, in adults, adolescents and children aged 5 years or older.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Clinical experience with Trientine dihydrochloride is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient&#39;s dose have not been well defined. Trientine dihydrochloride and penicillamine cannot be considered interchangeable. Trientine dihydrochloride should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Unlike penicillamine, Trientine dihydrochloride is not recommended in cystinuria or rheumatoid arthritis. The absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, Trientine dihydrochloride was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Trientine dihydrochloride is not indicated for treatment of biliary cirrhosis.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment should only be initiated by specialist physicians with experience in the management of Wilson&rsquo;s disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Posology</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The starting dose would usually correspond to the lowest recommended dose and the dose should subsequently be adapted according to the patient&rsquo;s clinical response (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Adults</p><p dir="ltr">The recommended dose is 750 - 1250 mg daily in 2 to 4 divided doses. This may be increased to a maximum of 2000 mg/day for adults.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The daily dose of Trientine dihydrochloride capsules should only be increased only when the clinical response is not adequate or the concentration of free serum copper is persistently above 20 mcg/dL. Optimal long-term maintenance dosage should be determined at 6-12 month intervals.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Special populations </u></em></p><p dir="ltr"><em>Elderly</em></p><p dir="ltr">There is insufficient clinical information available for Trientine diydrochloride to determine whether there exist differences in responses between the elderly and younger patients. In general, dose selection should be cautious, usually starting at the low end of the dosing range as recommended for adults, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Renal impairment</em></p><p dir="ltr">There is limited information in patients with renal impairment. Therefore, the recommended dose in patients with renal impairment is the same as for adults. For specific precautions see section 4.4.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hepatic impairment</em></p><p dir="ltr">There is limited information in patients with hepatic impairment. Therefore the recommended dose in patients with hepatic impairment is the same as for adults. For specific precautions see section 4.4.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Patients primarily presenting hepatic symptoms</em></p><p dir="ltr">The recommended dose in patients primarily presenting hepatic symptoms is the same as the recommended adult dose. It is advised, however, to monitor patients presenting with hepatic symptoms every two to three weeks after initiation of treatment with Trientine dihydrochloride capsules.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Patients primarily presenting neurological symptoms</em></p><p dir="ltr">Dose recommendations are the same as for adults. However, up titration should be done with moderation and consideration, and adapted according to the patient&rsquo;s clinical response such as worsening of tremor as patients could be at risk of neurological deterioration at initiation of treatment (see section 4.4). It is further advised to monitor patients presenting with neurological symptoms every one to two weeks after initiation of treatment with Trientine diydrochloride capsules until target dose is reached.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pediatric population</u></p><p dir="ltr">The dose is lower than for adults and depends on age and body weight. The dose should be adjusted according to clinical response; 500 &ndash; 750 mg/day in 2 to 4 divided doses have been used at initiation of therapy (see section 4.4). This may be increased to a maximum of 1500 mg/day for pediatric patients age 12 or under.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Children &lt; 5 years</em></p><p dir="ltr">The safety and efficacy of Trientine diydrochloride capsules in children aged 0 to 5 years have not yet been established. No data are available.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration </u></p><p dir="ltr">For oral use.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Capsules should be swallowed whole with water and should not be opened or chewed.</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is important that Trientine dihydrochloride capsules is given on an empty stomach, at least one hour before meals or two hours after meals, and at least one hour apart from any other medicinal product, food or milk (see section 4.5).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">When switching a patient from another trientine formulation, caution is advised because different trientine salts are available which may have a different trientine content (base) and a different bioavailability. Dose adjustment may be required (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Trientine is a chelating agent which has been found to reduce serum iron levels. Iron supplementation may be necessary in some cases. Concomitant oral iron should be administered at a different time than trientine (see section 4.5).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The combination of trientine with zinc is not recommended. There are only limited data on concomitant use available and no specific dose recommendations can be made.</p><p dir="ltr">&nbsp;</p><p dir="ltr">There is no evidence that calcium and magnesium antacids alter the efficacy of trientine but it is recommended to separate their administration (see section 4.5).</p><p dir="ltr">&nbsp;</p><p dir="ltr">There is no advantage in using trientine and penicillamine in combination.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients who were previously treated with D-Penicillamine, lupus-like reactions have been reported during subsequent treatment with trientine, however it is not possible to determine if there is a causal relationship with trientine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Monitoring</u></em></p><p dir="ltr">Patients receiving Trientine diydrochloride capsules should remain under regular medical supervision and be monitored using all available clinical data for appropriate control of clinical symptoms and copper levels in order to optimise treatment. Frequency of monitoring is recommended to be at least twice a year. More frequent monitoring is advised during the initial phase of treatment and during phases of disease progression or when dose adjustments are made as to be decided by the treating physician (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The aim of maintenance treatment is to maintain free copper levels in plasma (also known as non- ceruloplasmin plasma copper) and the urinary copper excretion within the acceptable limits.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The determination of serum free copper, calculated using the difference between the total copper and the ceruloplasmin-bound copper (normal level of free copper in the serum is usually 100 to 150 microgram/L), can be a useful index for monitoring therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The measurement of copper excretion in the urine may be performed during therapy. Since chelation therapy leads to an increase in urinary copper levels, this may/will not give an accurate reflection of the excess copper load in the body but may be a useful measure of treatment compliance.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The use of appropriate copper parameter target ranges is described in clinical practice guidelines related to Wilson&rsquo;s disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Like with all anti-copper agents, overtreatment carries the risk of copper deficiency, which is especially harmful for children and pregnant women (see section 4.6) since copper is required for proper growth and mental development. Therefore, monitoring for manifestations of overtreatment should be undertaken.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients with renal and/or hepatic impairment receiving trientine should remain under regular medical supervision for appropriate control of symptoms and copper levels. Close monitoring of renal and/or liver function is also recommended in these patients (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Worsening of neurological symptoms may occur at the beginning of chelation therapy due to excess of free serum copper during the initial response to treatment. It is possible that this effect may be more evident in patients with pre-existing neurological symptoms. It is recommended to monitor patients closely for such signs and symptoms and to consider careful titration to reach the recommended therapeutic dose and to reduce dose when necessary.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dose adjustments in the trientine dose should be considered in case of signs of reduced efficacy such as (persistent) increase in liver enzymes, and worsening of tremor. When trientine doses are adjusted this should be done in small steps. The trientine dose may also be reduced in case of side effects of trientine, such as gastrointestinal complaints and haematological changes. Trientine doses should be reduced to a more tolerable dose and may be increased again, once side effects have been resolved.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No interaction studies have been performed.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Zinc</u></p><p dir="ltr">There are insufficient data to support the concomitant use of zinc and trientine. The combination of trientine with zinc is not recommended as interaction of zinc with trientine is likely, thereby reducing the effect of both active substances.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Other anti-copper agents</u></p><p dir="ltr">No interaction studies have been performed on the concomitant administration of trientine with D- Penicillamine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Food</u></p><p dir="ltr">No specific food interaction studies in humans have been performed with trientine. However as trientine is poorly absorbed following oral intake, food may inhibit absorption. The principal mechanism of action of trientine requires its systemic exposure (see section 5.1) so it is recommended that trientine be taken at least 1 hour before meals or 2 hours after meals and at least one hour apart from any other medicinal product, food, or milk to allow for maximum absorption and reduce the likelihood of the formation of complexes by metal binding in the gastrointestinal tract (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Other products</u></p><p dir="ltr">Trientine has been found to reduce serum iron levels. Therefore, iron supplementation may be necessary in some cases. Concomitant oral iron or other heavy metals should be administered at a different time than trientine to prevent the formation of complexes (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Although there is no evidence that calcium and magnesium antacids alter the efficacy of trientine, it is good practice to separate their administration (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Pregnancy Category C</p><p dir="ltr">&nbsp;</p><p dir="ltr">There is a limited amount of data from the use of trientine in pregnant women.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Studies in animals have shown reproductive toxicity, which was probably a result of trientine-induced copper deficiency (see section 5.3). Trientine hydrochloride was teratogenic in rats at doses similar to the human dose. The frequencies of both resorptions and fetal abnormalities, including hemorrhage and edema, increased while fetal copper levels decreased when trientine hydrochloride was given in the maternal diets of rats.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Trientine should be used in pregnancy only after careful consideration of the benefits compared with the risks of discontinuing treatment in the individual patient. Factors to consider include the known risks associated with untreated or undertreated Wilson&rsquo;s disease, risks associated with the stage of disease, the risk of those alternative treatments which are available and the possible effects of trientine (see section 5.3).</p><p dir="ltr">&nbsp;</p><p dir="ltr">If treatment with trientine is to be continued following a risk-benefit analysis, consideration should be given to reducing the dose of trientine to the lowest effective dose and monitoring compliance with the treatment regimen.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The pregnancy should be closely monitored in order to detect possible foetal abnormality and to assess maternal serum copper levels throughout the pregnancy. The dose of trientine used should be adjusted in order to maintain serum copper levels within the normal range. Since copper is required for proper growth and mental development, dose adjustments may be required to ensure that the foetus will not become copper deficient and close monitoring of the patient is essential (see section 4.4)</p><p dir="ltr">&nbsp;</p><p dir="ltr">Babies born to mothers being treated with trientine should be monitored for serum copper and ceruloplasmin levels where appropriate.</p><p dir="ltr">Trientine dihydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breastfeeding</u></p><p dir="ltr">There is limited clinical data suggesting that trientine is not excreted in breast milk. However, a risk to the newborns/infants cannot be excluded.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Because many drugs are excreted in human milk, caution should be exercised when Trientine dihydrochloride is administered to a nursing mother. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from trientine therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">It is unknown whether trientine has an effect on human fertility.</p><p dir="ltr">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Trientine has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Gastrointestinal disorders (26% of patients), musculoskeletal and connective tissue disorders (19.5% of patients) and nervous system disorders (14.3% of patients) were the most common reported events attributed to trientine.</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">Nausea can commonly occur on initial treatment and occasionally skin rash can occur. Duodenitis and severe colitis have been reported. Neurological deterioration can occur at the start of the treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level). Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to</p><p dir="ltr">&lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><em>MedDRA- system organ class database</em></p></td><td style="vertical-align:top"><p><em>Adverse reaction</em></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Blood and lymphatic system disorders:</p></td><td style="vertical-align:top"><p>Uncommon: Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon: Aplastic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon: Sideroblastic anaemia</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Nervous system disorders:</p></td><td style="vertical-align:top"><p>Uncommon: Dystonia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon: Tremor</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Dysarthria</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Muscle rigidity</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Neurological deterioration</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders:</p></td><td style="vertical-align:top"><p>Not known: Lupus-like syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Lupus nephritis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders:</p></td><td style="vertical-align:top"><p>Common: Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Colitis</p></td></tr><tr><td style="vertical-align:top"><p>Not known: Duodenitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders:</p></td><td style="vertical-align:top"><p>Uncommon: Rash</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Description of selected adverse reactions</u></p><p dir="ltr">There have been reports of neurological deterioration at the start of treatment in Wilson&rsquo;s disease patients treated with copper chelators including trientine, with symptoms of, for example, dystonia, rigidity, tremor and dysarthria (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">The study on a limited number of children in the age range of 5 to 17 years at the start of treatment indicate that frequency, type and severity of adverse reactions in children are expected to be the same as in adults.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Experience with doses higher than the recommended therapeutic dose is limited. In the event of overdose the patient should be observed, appropriate biochemical analysis performed and symptomatic treatment given. There is no antidote.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In one reported case an overdose of 30 capsules did not produce any apparent adverse effects. In a second case, a large overdose of trientine (40 g) resulted in self-limiting dizziness and vomiting with no further clinical sequelae or significant biochemical abnormalities.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Chronic overtreatment can lead to copper deficiency and reversible sideroblastic anaemia. Overtreatment and excess copper removal can be monitored using values of urine copper excretion and of non-ceruloplasmin bound copper. Close monitoring is required to optimise the dose or adapt treatment if necessary (see section 4.4).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Other alimentary tract and metabolism, various alimentary tract and metabolism products, ATC code: A16AX12</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">Trientine is a copper-selective chelator that enhances systemic elimination of divalent copper by forming a stable complex that is readily excreted by the kidneys. Trientine is a chelator with a polyamine-like structure and copper is chelated by forming a stable complex with the four constituent nitrogens in a planar ring. Thus, the pharmacodynamic action of trientine is dependent on its chemical property of chelating copper and not on its interaction with receptors, enzyme systems or any other biological system that might differ between species. Trientine may also chelate copper in the intestinal tract and so inhibit copper absorption.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Weiss 2013 conducted a multicentre, retrospective observational study to compare the efficacy and safety of trientine versus penicillamine (DPA) in patients with WD (n=380) treated at tertiary care centres in Germany and Austria, and additional patients from the EUROWILSON registry (n=25). The cohort consisted of outcomes for patients with WD treated with DPA (n=326) and trientine (n=141)&nbsp;for at least six months. The primary efficacy outcome was the change in hepatic and neurologic outcomes (i.e. clinical symptoms and tests) at 6, 12, 24, 36, and 48&nbsp;months after initiation of the treatment regimen. Hepatic outcome measures were based on clinical symptoms, course of liver enzymes, and liver function tests. Patients with either of these clinical or biochemical signs of liver disease were considered symptomatic. The course of neurologic disease was evaluated by the physician.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In symptomatic hepatic patients, comparable rates of improvement were observed under first line d-penicillamine therapy (185 of 204; 90.7%) and first-line trientine therapy (25 of 27; 92.6%). In the same group, stable hepatic disease in terms of unchanged hepatic symptoms was observed for first-line d-penicillamine therapy treatment in 15 of 204 (7.4%) treatments versus 2 of 27 (7.4%) in the trientine group.&nbsp; Stable hepatic disease under second-line therapy was reported for 4 of 16 (25%) d-penicillimine treatments and for 10 of 45 (22.2%) trientine treatments. No hepatic worsening was seen in chelation monotherapy for patients who presented without hepatic symptoms.&nbsp; No statistically significant differences were found for the rate of improvement for first-line (d-penicillamine 77 of 114, 67.5% versus trientine 11 of 20, 55%) or second-line (d-penicillamine 3 of 13, 23.1% versus trientine 26 of 51, 51%) chelation therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Stable neurologic disease was observed for first-line in the d-penicillamine group in 31 of 114 (27.2%) treatments versus 5 of 20 (25%) in the trientine group. Stable neurologic disease for second-line therapy was reported for 9 of 13 (69.2%) d- penicillamine treatments and for 17 of 51 (33.3%) trientine treatments. With second-line therapy, neurologic worsening was comparable between groups, with a trend favoring d-penicillamine (d-penicillamine: 1 of 13, 7.3%; trientine: 8 of 51, 15.7%).&nbsp; &nbsp;A significantly higher rate of neurologic worsening was reported for first-line therapies of symptomatic neurologic patients treated with trientine (4 of 20; 20%) versus d-penicillamine (6 of 114; 5.3%) (p=0.042).</p><p dir="ltr">&nbsp;</p><p dir="ltr">There were no differences between the treatments based on the number of overall discontinuations (p=0.36) with 142/326 (43.6%) discontinuing from d-penicillamine and 36/141 (25.5%) from trientine therapy.&nbsp; Discontinuation as a result of adverse events was more frequent for d-penicillamine treatment than for trientine treatment with 94/326 (28.8%) of DPA treatments stopped because of adverse events versus 10/141 (7.1%) of trientine treatments (p=0.039).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Weiss 2018 conducted a multicentre, retrospective cohort study of medical records to evaluate the efficacy, safety and tolerability of trientine for at least 6&nbsp;months as a second-line treatment in patients with WD (n=77). The study also included a prospective part which was a continuation of the retrospective study (n=52) to assess efficacy and quality of life (QoL) outcomes.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The efficacy endpoint was the clinical course of hepatic or neurological disease based on the Investigator&rsquo;s scores at the time of initiating trientine (similar 5-point score as used in the Weiss 2013 study), and 6, 12, 24, 36, 48 months and at the last available time point while taking second line trientine and the time to discontinuation of trientine due to AE and/or inadequate response. Copper storage and metabolism were measured as surrogate endpoints at the time of initiation, and 6, 12, 24, 36, 48 months and at the last available time point after initiation of trientine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">A total of 77 patients were included in the intention to treat (ITT) population.&nbsp; A total of 38 (49.4%) patients showed improved hepatic symptoms with 17 (22.1%) patients classified as &lsquo;improved to normal&rsquo; and 21 (27.3%) patients classified as &lsquo;improved but not normal&rsquo;, 27 (35.1%) patients were &lsquo;asymptomatic&rsquo; and 8 (10.4%) patients had &lsquo;unchanged&rsquo; symptoms, and&nbsp; 4 (5.2%) patients had &lsquo;worsened symptoms&rsquo;.&nbsp; A total of 11 (14.3%) patients showed improved neurological symptoms with 2 (2.6%) patients classified as &lsquo;improved to normal&rsquo; and 9 (11.7%) patients classified with &lsquo;improved but not normal&rsquo;, 36 (46.8%) patients were &lsquo;asymptomatic&rsquo; and 28 (36.4%) patients had &lsquo;unchanged&rsquo; symptoms, and 2 (2.6%) patients had &lsquo;worsened symptoms&rsquo;.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Within the two years of observation, 12 (15.6%) of patients discontinued trientine and switched to another treatment option. At the individual last available observation, treatment with trientine was ongoing in 65 (84.4%) patients of the ITT population.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The Weiss 2019 study was a prospective study and a continuation of Weiss 2018 with an additional QoL objective. All patients had been enrolled in the retrospective study and were continued to be observed in the prospective study. The mean age was 42.3 &plusmn; 14.52 years.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Fifty of the 51 patients (98.0%) treated with trientine were considered to have responded to treatment, while only one patient (2.0%) showed a mild worsening of disease at 12 months.&nbsp; For neurological presentations, the neurological symptoms improved but not to normal in eight patients (15.7%), and improved to normal in one patient (2.0%). A total of 29 (56.9%) patients were asymptomatic over the duration of therapy. In 12 patients (23.5%) symptoms remained unchanged and there was one patient (2.0%) with worsening of neurological symptoms. The UWDRS neurologic subscale assessment was 11.3 &plusmn; 24.31 at baseline, 9.7 &plusmn; 23.85 at month 6 and 8.8 &plusmn; 22.86 at month 12 which indicated a neurological improvement.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The mean 24&nbsp;h basal urine copper excretion was similar at month 6 and month 12 (4.011&nbsp;&micro;mol/24 h versus 4.452 &micro;mol/24 h, respectively); the mean serum copper at baseline was 4.505 &plusmn; 3.4036 &micro;mol/L, 4.648 &plusmn; 2.9990&nbsp;&micro;mol/L at month 6 and at 4.753 &plusmn; 3.6092 &micro;mol/L at month 12; and the mean non-ceruloplasmin bound copper (NCC) concentration at month 6 was 1.1542 &plusmn; 0.92618 &micro;mol/L and 0.9051 &plusmn; 0.88075 &micro;mol/L at month 12.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The QoL data indicated that overall, the anxiety and depression improved during treatment with trientine. The other QoL indicators (mobility, self-care, usual activities and pain/discomfort) were stable and generally similar at month 6 and month 12.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Forty-one patients (18 male and 23 female) between the ages of 6 and 54 with a diagnosis of Wilson&rsquo;s disease and who were intolerant of d-penicillamine were treated in two separate studies with trientine dihydrochloride. The dosage varied from 450 to 2400 mg per day. The average dosage required to achieve an optimal clinical response varied between 1000 mg and 2000 mg per day. The mean duration of trientine dihydrochloride therapy was 48.7 months (range 2-164 months). Thirty-four of the 41 patients improved, 4 had no change in clinical global response, 2 were lost to follow-up and one showed deterioration in clinical condition. One of the patients who improved while on therapy with trientine dihydrochloride experienced a recurrence of the symptoms of systemic lupus erythematosus which had appeared originally during therapy with penicillamine. Therapy with trientine dihydrochloride was discontinued. No other adverse reactions, except iron deficiency, were noted among any of these 41 patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr">One investigator treated 13 patients with trientine dihydrochloride following their development of intolerance to d-penicillamine. Retrospectively, the investigator compared these patients to an additional group of 12 patients with Wilson&rsquo;s disease who were both tolerant of and controlled with d-penicillamine therapy, but who failed to continue any copper chelation therapy. The mean age at onset of disease of the latter group was 12 years as compared to 21 years for the former group. The trientine dihydrochloride group received d-penicillamine for an average of 4 years as compared to an average of 10 years for the non-treated group.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Various laboratory parameters showed changes in favor of the patients treated with trientine dihydrochloride. Free and total serum copper, SGOT and serum bilirubin all showed mean increases over baseline in the untreated group which were significantly larger than with the patients treated with trientine dihydrochloride. In the 13 patients treated with trientine dihydrochloride, previous symptoms and signs relating to d-penicillamine intolerance disappeared in 8 patients, improved in 4 patients, and remained unchanged in one patient. The neurological status in the trientine dihydrochloride group was unchanged or improved over baseline, whereas in the untreated group, 6 patients remained unchanged and 6 worsened. Kayser-Fleischer rings improved significantly during trientine dihydrochloride treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The clinical outcome of the two groups also differed markedly. Of the 13 patients on therapy with trientine dihydrochloride (mean duration of therapy 4.1 years; range 1 to 13 years), all were alive at the data cutoff date, and in the non-treated group (mean years with no therapy 2.7 years; range 3 months to 9 years), 9 of the 12 died of hepatic disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Chelating Properties</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><em>Preclinical Studies</em></strong></p><p dir="ltr">Studies in animals have shown that trientine dihydrochloride has cupriuretic activities in both normal and copper-loaded animals.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><em>Human Studies</em></strong></p><p dir="ltr">Renal clearance studies were carried out with penicillamine and trientine dihydrochloride on separate occasions in selected patients treated with penicillamine for at least one year. Six-hour excretion rates of copper were determined off treatment and after a single dose of 500 mg of penicillamine or 1.2 g of trientine dihydrochloride. The mean urinary excretion rates of copper were as follows:</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients not previously treated with chelating agents, a similar comparison was made:</p><p dir="ltr">&nbsp;</p><p dir="ltr">These results demonstrate that trientine dihydrochloride is effective as a cupriuretic agent in patients with Wilson&rsquo;s disease although on a molar basis it appears to be less potent or less effective than penicillamine. Evidence from a radio-labelled copper study indicates that the different cupriuretic effect between these two drugs could be due to a difference in selectivity of the drugs for different copper pools within the body.</p><p dir="ltr">&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Absorption</u></p><p dir="ltr">Following oral administration, trientine absorption is low and variable in patients with Wilson&rsquo;s disease. Trientine is absorbed with Tmax occurring between 0.5 and 4&nbsp;hours post-dose in healthy volunteers and patients. Exposure seems to be highly variable between subjects. The terminal half-life in plasma is approximately 13.5&nbsp;h.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">Trientine has low human plasma protein binding and is widely distributed in tissues with relatively high concentrations measured in liver, heart, and kidney in the rat.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Biotransformation</u></p><p dir="ltr">Trientine is acetylated in two major metabolites, N(1)-acetyltriethylenetetramine (MAT) and N(1),N(10)-diacetyltriethylenetetramine (DAT). The extent of MAT and DAT&rsquo;s contribution to the overall effect of Cufence on copper levels in Wilson&rsquo;s Disease patients remains to be determined.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Trientine is metabolised by acetylation via spermidine/spermine N-acetyltransferase and not via N-acetyltransferase 2.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">Trientine and its metabolites are rapidly excreted in the urine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Unabsorbed trientine is bound to intestinal copper and eliminated through faecal excretion.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">&nbsp;</p><p dir="ltr">Non-clinical data reveal no special hazard for humans based on a series of studies investigating cardiovascular safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to embryofoetal development.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Effects in non-clinical studies were largely consistent with induced copper deficiency in the plasma and liver of previously copper normative animals and as such could be attributed to the pharmacological action of trientine. The main toxicological findings associated with trientine, which were generally seen across all species examined, included body weight loss or lower body weight gain, altered urinary electrolytes, low plasma copper levels and various histopathological changes in the lungs (mainly interstitial pneumonitis). All effects were reversible with the exception of the lung findings; however the dose levels where these effects were observed are far in excess of those used clinically. Moreover, there was some doubt about the relationship to trientine, as the lung findings were also observed in most of the control dogs in the 26 week study. In dogs, ataxia, tremors, abnormal gait and underactivity were observed following administration of very high levels of trientine. Some functional neurological abnormalities were also identified, particularly in severly affected animals, however no associated nerve damage was observed. Electrocardiography was also unaffected.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In pregnant animals, high dose trientine associated with significant reductions in serum copper, revealed an early effect on embryo survival and a marginally lower foetal weight. There was no evidence of embryo-foetal toxicity at lower dose levels despite dose-related reductions in serum copper. These effects were observed only at exposures sufficiently in excess of maximum human exposure to indicate little relevance to clinical use.</p><p dir="ltr">&nbsp;</p><p dir="ltr">No fertility data are available but estrous cyclicity was unaffected and reproductive organs were not identified as target organs in general repeat dose toxicity studies.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The OECD SIDS triethylenetetramine 2002 classifies the genotoxic profile of trientine as low priority/concern. Some positive <em>in vitro </em>mutagenicity data were obtained but <em>in vivo </em>test systems showed no mutagenic activity. No long term animal carcinogenicity trials have to date been performed with trientine via the oral route, but via the dermal route, there was no increases in cancers above baseline. Moreover, there is evidence to suggest that trientine actually reduces endogenous DNA damage in a strain of rat (Long-Evans Cinnamon) considered to represent an appropriate model of Wilson&rsquo;s disease. This suggests a reduced carcinogenic risk for Wilson&rsquo;s disease patients as a result of trientine therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Trientine dihydrochloride is a known irritant, especially to mucus membranes, upper respiratory tract and skin, and induces skin sensitisation in guinea pigs, mice and man (OECD SIDS triethylenetetramine 2002).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p dir="ltr"><u>Capsule content: </u></p><p dir="ltr">Stearic acid</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Capsule shell: </u></p><p dir="ltr">Gelatin</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">FD&amp;C Yellow 6 (E110)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store in a refrigerator (2&ordm;C-8&ordm;C). Do not freeze.</p><p dir="ltr">Keep the container tightly closed. Store in the original container and retain the silica gel strip in the bottle in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">&nbsp;</p><p dir="ltr">White HDPE bottle with polypropylene cap and induction heat seal liner with a strips of silica gel as desiccant..</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pack size: 1 bottle of 100 hard capsules</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Navinta LLC,
1499 Lower Ferry Road,
Ewing, NJ-08618-1414, USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2020.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>